Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management

Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management

<b>Background</b>: Plexiform neurofibromas (pNFs) are benign neoplasms, primarily originating from Schwann cells, posing challenges in patients with type 1 neurofibromatosis (NF1) due to pain, disfigurement, compression of vital structures and potential for malignancy. Selumetinib, a MEK...

Full description

Bibliographic Details
Main Authors: Paola Borgia, Gianluca Piccolo, Andrea Santangelo, Cristina Chelleri, Gianmaria Viglizzo, Corrado Occella, Carlo Minetti, Pasquale Striano, Maria Cristina Diana
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Journal of Clinical Medicine
Subjects:
pediatric dermatology
prevention
management
selumetinib
NF1
neurofibromatosis type 1
Online Access:https://www.mdpi.com/2077-0383/13/6/1792

Similar Items

Similar Items